A professional tesamorelin purchase process should start before the quotation.
First, define the specification.
Then identify suitable suppliers.
Next, compare analytical records.
Finally, approve the batch.
This process works especially well for laboratories, biotechnology companies, CROs, and scientific distributors.
Tesamorelin has a well-defined molecular identity.
DailyMed describes it as a synthetic 44-amino-acid human GRF analog with an added hexenoyl group. Its free-base-equivalent molecular weight is approximately 5,135.9 Da.
Therefore, an RFQ should contain more than the word “Tesamorelin.”
A useful RFQ can specify:
This reduces quotation errors.
For peptide procurement, identity and purity answer different questions.
HPLC primarily gives chromatographic information.
Mass spectrometry can support molecular identity.
FDA peptide-quality research describes LC-MS and LC-MS/MS as powerful tools for peptide mixture and impurity analysis.
Therefore, requesting both types of data can strengthen supplier qualification.
| Requirement | Minimum RFQ | Preferred RFQ |
|---|---|---|
| Compound | Tesamorelin | Tesamorelin + identity specification |
| Purity | Target % | Target % + HPLC report |
| Identity | Supplier statement | MS / LC-MS result |
| Documentation | COA | Lot-specific COA |
| Supply | One order | Repeat-batch capability |
A supplier can have a polished website but weak documentation.
Therefore, evaluate the company and product separately.
Current research-market pages commonly show purity specifications around 99% or higher. Several also advertise third-party testing, HPLC, MS, or batch-specific COAs.
However, those are commercial claims.
The buyer should verify the corresponding records.
Ask:
Who performed the test?
Which lot did the laboratory test?
Does the report identify tesamorelin?
Does the vial carry the same lot number?
These questions improve traceability quickly.
Repeat orders can create another problem.
A good first batch does not automatically guarantee the same result later.
Therefore, treat every new lot as a new quality event.
For example:
A CRO purchases 100 mg from Batch A.
The HPLC result meets its internal specification.
Three months later, the CRO needs another 100 mg.
Instead of relying on the previous COA, the purchasing team requests the new Batch B report.
This small step reduces assumptions.
It also improves project records.
This distinction is essential for tesamorelin.
FDA’s Purple Book currently lists Egrifta, Egrifta SV, and Egrifta WR as licensed biological products under BLA 022505.
EGRIFTA WR is Rx only.
Its vial contains 11.6 mg tesamorelin. The product uses controlled pharmaceutical labeling and defined formulation components.
Research materials follow another supply chain.
As a result, procurement teams should never use the terms interchangeably.
| Factor | Prescription Product | Research Peptide |
|---|---|---|
| Example | EGRIFTA WR | Supplier-listed tesamorelin |
| Access | Prescription pharmacy | Scientific procurement |
| Specification | Approved formulation | Vendor-defined |
| Batch Review | Pharmaceutical controls | Buyer should review COA |
| Substitution | Use as labeled | Not a pharmaceutical substitute |
Imagine a distributor receives a request for 500 mg of peptide material.
Instead of asking only for a bulk price, the buyer sends a structured RFQ.
The request includes:
Tesamorelin peptide material
Total requirement: 500 mg
Lot-specific COA required
HPLC chromatogram required
MS identity data required
Please specify batch size and lead time
Please confirm packaging options
Please confirm repeat-batch capability
Now three suppliers can quote on the same basis.
Without this structure, one supplier may quote crude material.
Another may quote highly purified material.
A third may quote a different packaging configuration.
The prices would look comparable.
In reality, they would not be.
Educational purchasing pages should also explain why the molecule attracts scientific interest.
In two pivotal studies, the original tesamorelin formulation produced mean 26-week VAT changes of -18% and -14%. Placebo groups showed +2% and -2%.
The official label also reports increases in IGF-1 during treatment.
However, these data apply to studied clinical populations and formulations.
They should not become generalized marketing claims for unapproved products.
That nuance strengthens credibility.
Use this sequence:
Specification → Supplier → COA → HPLC → MS → Lot → Quantity → Quote → Batch Approval → Repeat Verification
For larger purchases, this process can save more than chasing the lowest unit cost.
